ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Market Capitalization on January 14, 2025: USD 981.42 M

ABL Bio Inc. Market Capitalization is USD 981.42 M on January 14, 2025, a 19.45% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ABL Bio Inc. 52-week high Market Capitalization is USD 1.46 B on October 14, 2024, which is 48.50% above the current Market Capitalization.
ABL Bio Inc. 52-week low Market Capitalization is USD 712.95 M on February 08, 2024, which is -27.36% below the current Market Capitalization.
ABL Bio Inc. average Market Capitalization for the last 52 weeks is USD 965.18 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years